|
Synonyms: MRTX-2219 | ORIC-944 | ORIC944
Compound class:
Synthetic organic
Comment: Rinzimetostat (ORIC-944, formerly MRTX-2219) is an orally bioavailable allosteric inhibitor that blocks histone binding at H3K27me3 by targeting the EED subunit of the polycomb repressive complex 2 (PRC2). This disrupts the repressive function of H3K27me3, and is proposed as a mechanism to promote tumour growth inhibition. EED inhibition is proposed as an alternative to inhibition of EZH2-mediated PRC2 function.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||